1α,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3371-3379

  Swami, Srilatha ^a   Krishnan, Aruna V ^a   Feldman, David ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALCITRIOL; CYCLOHEXIMIDE; DACTINOMYCIN; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; LEXACALCITOL; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN; RO 27 0574; SEOCALCITOL; UNCLASSIFIED DRUG; ANTIESTROGEN; DRUG DERIVATIVE; ESTROGEN RECEPTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENCY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BREAST NEOPLASMS; CALCITRIOL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG INTERACTIONS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; HUMANS; RECEPTORS, ESTROGEN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033624178     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Ferguson, A., and Davidson, N. Regulation of estrogen receptor α function in breast cancer. Crit. Rev. Oncog., 8: 29-46, 1997.
3. Mangelsdorf, D., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. The nuclear receptor superfamily: the second decade. Cell, 83: 835-839, 1995.
4. Feldman, D., Malloy, P. J., and Gross, C. Vitamin D: metabolism and action. In: R. Marcus, D. Feldman, and J. Kelsey (eds.), Osteoporosis, pp. 205-235. San Diego: Academic Press, Inc., 1996.
5. Haussler, M. R., Whitfield, G. K., Haussler, C. A., Hsieh, J. C., Thompson, P. D., Selznick, S. H., Dominguez, C. E., and Jurutka, P. W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res., 13: 325-349, 1998.
6. Malloy, P. J., Pike, W. J., and Feldman, D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D resistant rickets. Endocr. Rev., 20: 156-188, 1999.
7. Bikle, D. Vitamin D and skin. In: D. Feldman, F. Glorieux, and J. Pike (eds.), Vitamin D, pp. 379-394. San Diego: Academic Press, Inc., 1997.
8. van Leeuwen, J., and Pols, H. Vitamin D: anticancer and differentiation. In: D. Feldman, F. Glorieux, and J. Pike (eds.), Vitamin D, pp. 1089-1105. San Diego: Academic Press, Inc., 1997.
9. Pike, J. W. The vitamin D receptor and its gene. In: D. Feldman, F. Glorieux, and J. Pike (eds.), Vitamin D, pp. 105-126. San Diego: Academic Press, Inc., 1997.
10. Colston, K. W., Chander, S. K., Mackey, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogs on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693-702, 1992.
11. 3 analogues and tamoxifen. Cancer Res., 54: 5711-5717, 1994.
12. 3 analogs in breast cancer cells. Cancer Res., 56: 2789-2794, 1996.
13. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat., 42: 31-41, 1997.
14. James, S. Y., Mackey, A. G., Binderup, L., and Colston, K. W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol., 141: 555-563, 1994.
15. 3 in T47D human breast cancer cells. J. Steroid Biochem. Mol. Biol., 54: 147-153, 1995.
16. 3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. Cancer Res., 54: 1458-1464, 1994.
17. 3 derivatives and breast cancer. In: M. Tenniswood and H. Michna (eds.), Schering Foundation Workshop, Vol. 14, pp. 201-224. Berlin: Springer Verlag, 1995.
18. Saceda, M., Lippman, M. E., Chambon, P., Lindsey, R. L., Ponglikitmongkol, M., Puente, M., and Martin, M. B. Regulation of estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol., 2: 1157-1162, 1988.
19. 3 receptor gene expression and enhances hormone action. Mol. Endocrinol., 6: 198-206, 1992.
20. Burton, K. A study of conditions and mechanisms of the diphenylamine colorimetric estimation of deoxyribonucleic acid. Biochem. J., 62: 315-323, 1956.
21. Malloy, P. J., Hochberg, Z., Pike, J. W., and Feldman, D. Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D rickets, type II. J. Clin. Endocrinol. Metab., 68: 263-269, 1989.
22. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72: 248-254, 1976.
23. Skowronski, R. J., Peehl, D. M., and Feldman, D. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952-1960, 1993.
24. 3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
25. Stott, D. Analysis of transcriptional initiation in isolated nuclei. In: E. J. Murray (ed.), Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols, pp. 327-335. Clifton, NJ: The Humana Press, Inc., 1991.
26. Lippman, M. E., Bolan, G., and Huff, K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res., 36: 4595-4601, 1976.
27. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J-M., Argos, P., and Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (Lond.), 320: 134-139, 1986.
28. Watanabe, T., Inoue, S., Ogawa, S., Ishii, Y., Hiroi, H., Ikeda, K., Orimo, A., and Muramatsu, M. Agonistic effect of tamoxifen dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β, Biochem. Biophys. Res. Commun., 236: 140-145, 1997.
29. Dotzlaw, H., Leygue, E., Watson, P. H., and Murphy, L. C. Expression of estrogen receptor-β in human breast tumors. J. Clin. Endocrinol. Metab., 82: 2371-2374, 1996.
30. Fuqua, S., Schiff, R., Parra, I., Friedrichs, W. E., Su, J-L., McKee, D. D., Slentz-Kesler, K., Moore, L. B., Willson, T. M., and Moore, J. T. Expression of wild-type estrogen receptor β and variant isoforms in human breast cancer. Cancer Res., 59: 5425-5428, 1999.
31. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J. Steroid. Biochem., 24: 373-376, 1986.
32. 3-resistant MCF-7 cell line. Endocrinology, 137: 400-409, 1996.
33. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol., 42: 1569-1575, 1991.
34. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84: 1960-1968, 1994.
35. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
36. Mathiasen, I. S., Colston, K. W., and Binderup, L. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J. Steroid Biochem. Mol. Biol., 46: 365-371, 1993.
37. Veyron, P., Pamphile, R., Binderup, L., and Touraine, J. L. Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transplant. Immunol., 1: 72-76, 1993.
38. 3. Proc. Natl. Acad. Sci. USA., 87: 8097-8101, 1992.
39. 3 responsive represser sequences in the rat parathyroid hormone-related peptide gene. J. Biol. Chem., 271: 16310-16316, 1996.
40. Miki, Y., Swenson, J., Shattuck-Eldens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Kazuko, Y., Gholami, Z., Shaffler, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayanath, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvring, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Weisman, R., Kamb, A., and Skolnick, M. H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Washington DC), 266: 66-71, 1994.
41. Brody, L., and Biesecker, B. Breast cancer susceptibility genes BRCA1 and BRCA2. Medicine (Baltimore), 77: 208-226, 1998.
42. Paterson, J. BRCA1: a review of structure and putative function. Dis. Markers, 13: 261-274, 1998.
43. Gudas, J. M., Nguyen, H., Li, T., and Cowan, K. H. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res., 55: 4561-4565, 1995.
44. Marquis, S. T., Rajan, J. V., Wynshaw-Boris, A., Xu, J., Yin, G. Y., Abel, K. J., Weber, B. L., and Chodosh, L. A. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet., 11: 17-26, 1995.
45. Gudas, J. M., Li, T., Nguyen, H., Jensen, D., Rauscher, F. J. I., and Cowan, K. H. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ., 7: 717-723, 1996.
46. Marks, J. R., Huper, G., Vaughn, J. P., Davis, P. L., Norris, J., McDonnell, D. P., Wiseman, R. W., Futreal, P. A., and Iglehart, J. D. BRCA1 expression is not directly responsive to estrogen. Oncogene, 14: 15-21, 1997.
47. 3 analogs and their 24-oxometabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell. Biochem., 66: 413-425, 1997.
48. 3 (calcitriol). J. Urol., 159: 2035-2039, 1998.